Form D · Biotechnology
Proteoform Scientific Inc.
Halifax, A5 · CIK 0001784343
Offering snapshot reported Nov 9, 2021 · SEC filing
- Reported sold
- $595K Offering amount: $3M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 27, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 9, 2021 | Initial | $594,681 | No comparison | 10 | SEC filing |
| Aug 2, 2019 | Initial | $290,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $225K
- Form D file number
- 021-420528
Alexander Capital L.P. (the "Finder") to receive a cash Finder's Fee of 7.5% of gross proceeds from subscribers who are introduced by the Finder to the Issuer. Estimate assumes full offering is sold to subscribers introduced by the Finder.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Alexander Capital L.P. | 40077 |
Source: Form D, filed Nov 9, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kevin Buchan | Director, Executive, Promoter |
| Alan Doucette | Director |
| Peter Hickey | Director, Executive |
| Ali Riaz | Director, Executive |
| Neil Smith | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1344 Summer Street
Halifax, A5, B3H 0A8
Halifax, A5, B3H 0A8